Headwinds for Pfizer

Pfizer . (NYSE:PFE) is one of the largest pharmaceutical companies in the US. But the company is facing several headwinds in its business. Pfizer . (NYSE:PFE) has a healthy dividend yield of 3.8%. But analysts think that dividend should not be the only factor while evaluating a possible investment. Pfizer . (NYSE:PFE)’s Prevnar13 pneumococcal vaccine, one of the major streams of revenue, is expected to be flat this year amid market saturation.

Pfizer ’s breast cancer drug Ibrance is also expected to experience declining sales due to Eli Lilly's (NYSE:LLY) abemaciclib and Novartis ' Kisqali.

Last week, Citigroup downgraded Pfizer . (NYSE:PFE)’s to “Neutral” and cut its price target to $31 from $38. The firm thinks Pfizer . (NYSE:PFE)’s oncology drugs are under threat due to their high prices and increasing market competition.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.